WinDiab

Düsseldorf, Germany
Düsseldorf, Germany
SEARCH FILTERS
Time filter
Source Type

Adamczewski H.,Diabetologische Schwerpunktpraxis | Weber D.,Diabetologische Schwerpunktpraxis | Heinemann L.,Windiab | Kaltheune M.,Diabetologische Schwerpunktpraxis
Diabetes, Stoffwechsel und Herz | Year: 2010

'GestDiab' is an ongoing project monitoring the treatment of pregnant women in diabetes specialist practices (DSPs). In 2008, data on anamnesis, diagnosis, therapy, delivery, and incidence of complications in the mother and the newborn were collected from 1075 pregnant women with diabetes (gestational: 1 005; type 1: 40; type 2: 30) across 16 DSPs. Women with gestational diabetes showed up for an average of 8.2 consultations and/or training sessions (median = 7). Of the women who delivered, the number of caesarean sections was only slightly more frequent than in the general population (33% vs. 31 %). Post partum diabetes screening by means of a 75 g OGTT was carried out in 32 % of the women who had had gestational diabetes. The OGTT revealed a pathologic result in 52 % of cases including 4 % diabetes diagnoses. Women with type 2 diabetes were found to differ from those with type 1 diabetes in that they presented themselves less frequently for pre-conceptional care (40 % vs. 73 %), were more often smokers (25% vs. 11 %), had higher BMIs (mean 32.9 vs. 25.7 kg/m2), but fewer disorders secondary to diabetes (3% vs. 30%). Our evaluation revealed that routine treatment had not always been carried out according to the latest scientific knowledge and guidelines.


Weber D.,WinDiab | Haastert B.,WinDiab | Kaltheuner M.,WinDiab | Heinemann L.,WinDiab
Diabetes, Stoffwechsel und Herz | Year: 2014

Improvement targets in metabolic control and/or reduction in bodyweight are a frequent issue in daily practice when considering a change in therapy for a given patient. Results from evaluating patients treated in specialist diabetes practices using a DPP-4 inhibitor or a GLP-1 analogue for one year, or ceasing this line of therapy beforehand, were used for calculating the probability of achieving HbA1c and BMI target values in a given patient. The calculator requires a few values to be keyed induration of diabetes, BMI, insulin therapy before starting the new therapy (yes or no), insulin dose and HbA1c at baseline. This contribution presents the calculator and the underlying statistical models, and discusses limitations to this approach. The availability of therapy outcome predictions using a certain drug may provide valuable support in patient consultations.

Loading WinDiab collaborators
Loading WinDiab collaborators